We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+30.33%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.67B
AUM Growth
+$284M
Cap. Flow
-$40.3M
Cap. Flow %
-2.41%
Top 10 Hldgs %
68.77%
Holding
48
New
7
Increased
25
Reduced
10
Closed
2

Top Buys

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$39.7M
2
ESTA icon
Establishment Labs
ESTA
+$19.9M
3
VRAY
ViewRay, Inc.
VRAY
+$18.8M
4
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$18.2M
5
RMD icon
ResMed
RMD
+$16.1M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$90.8M
2
RGNX icon
Regenxbio
RGNX
+$44.7M
3
PTCT icon
PTC Therapeutics
PTCT
+$33M
4
SLDB icon
Solid Biosciences
SLDB
+$17.3M
5
ARWR icon
Arrowhead Research
ARWR
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$348M
$369M 22.07%
14,969,744
– –
PTCT icon
2
PTC Therapeutics
PTCT
$6.37B
$154M 9.22%
3,275,591
-798,099
-20% -$33M
ARWR icon
3
Arrowhead Research
ARWR
$12.1B
$146M 8.73%
7,604,225
-695,317
-8% -$11.4M
RGNX icon
4
Regenxbio
RGNX
$623M
$110M 6.6%
1,459,128
-620,427
-30% -$44.7M
DRNA
5
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$83.3M 4.99%
5,461,124
+416,311
+8% +$6.06M
PRQR icon
6
ProQR Therapeutics
PRQR
$243M
$72.4M 4.33%
+3,739,406
New +$39.7M
BMY icon
7
Bristol-Myers Squibb
BMY
$127B
$58.8M 3.52%
946,961
+43,289
+5% +$2.57M
LIVN icon
8
LivaNova
LIVN
$4.3B
$54.9M 3.29%
443,036
+12,036
+3% +$1.42M
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.66B
$50.7M 3.04%
314,070
-664,481
-68% -$90.8M
ACHN
10
DELISTED
Achillion Pharmaceuticals
ACHN
$50M 3%
13,595,704
+53,707
+0.4% +$160K
MASI
11
DELISTED
Masimo
MASI
$38.7M 2.32%
310,461
+60,918
+24% +$6.76M
ABUS icon
12
Arbutus Biopharma
ABUS
$865M
$38.6M 2.31%
4,084,904
-1,080,595
-21% -$10.7M
CORI
13
DELISTED
Corium International, Inc.
CORI
$34.3M 2.06%
3,610,632
+1,687,415
+88% +$14.5M
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$36.3B
$34.1M 2.04%
389,072
+36,872
+10% +$3.71M
VRAY
15
DELISTED
ViewRay, Inc.
VRAY
$31.7M 1.9%
3,389,498
+1,915,342
+130% +$18.8M
VCEL icon
16
Vericel Corp
VCEL
$2.3B
$31.4M 1.88%
2,217,916
– –
ILMN icon
17
Illumina
ILMN
$29.4B
$30.3M 1.82%
84,934
+33,886
+66% +$10.9M
QGEN icon
18
Qiagen
QGEN
$8.53B
$29.4M 1.76%
731,174
+231,935
+46% +$9.27M
LJPC
19
DELISTED
La Jolla Pharmaceutical Company
LJPC
$24.1M 1.44%
1,197,107
-148,774
-11% -$3.89M
AGEN
20
Agenus
AGEN
$249M
$21M 1.26%
500,562
+22,883
+5% +$901K
ESTA icon
21
Establishment Labs
ESTA
$2.72B
$18.1M 1.08%
+775,809
New +$19.9M
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$17.9M 1.07%
273,917
+12,522
+5% +$736K
PRNB
23
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$17.4M 1.04%
+644,448
New +$18.2M
RMD icon
24
ResMed
RMD
$28.3B
$17M 1.02%
+147,400
New +$16.1M
APYX icon
25
Apyx Medical
APYX
$165M
$15.9M 0.95%
2,235,547
+153,410
+7% +$853K
1
2

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q3 2018 Portfolio in Review

As of Q3 2018, RTW Investments held 48 positions worth $1.67B, up 20% from $1.39B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

RTW Investments's Q3 2018 filing shows 7 new, 25 increased, 10 reduced and 2 closed positions. Its largest new stake was ProQR Therapeutics: 3,739,406 shares worth $72.4M. The largest sale was Sarepta Therapeutics, an estimated $90.8M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier.

  • RTW Investments's largest Q3 2018 buy was ProQR Therapeutics: 3,739,406 shares worth $72.4M.
  • RTW Investments added most to ViewRay, Inc. in Q3 2018, an estimated $18.8M increase.
  • RTW Investments's biggest Q3 2018 reduction was Sarepta Therapeutics, cutting an estimated $90.8M.
  • RTW Investments fully exited PolarityTE, Inc. Common Stock in Q3 2018, selling an estimated $10M.
  • RTW Investments's ten largest holdings make up 69% of its $1.67B portfolio in Q3 2018.
  • RTW Investments opened 7 new positions and closed 2 in Q3 2018.
  • RTW Investments's portfolio value rose 20% quarter-over-quarter to $1.67B.

Based on RTW Investments's 13F filing for Q3 2018, filed 14 Nov 2018.